Cleared Traditional

K213911 - Microstream CO2 NanoPod (FDA 510(k) Clearance)

Class II Anesthesiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K213911 · Covidien, LLC · Anesthesiology device

Download Printable Device Report (PDF)

Optimized for regulatory review, auditing and printing

Jul 2022

Decision

226d

Days

Class 2

Risk

K213911 is an FDA 510(k) clearance for the Microstream CO2 NanoPod. Classified as Analyzer, Gas, Carbon-dioxide, Gaseous-phase (product code CCK), Class II - Special Controls.

Submitted by Covidien, LLC (Boulder, US). The FDA issued a Cleared decision on July 29, 2022 after a review of 226 days - an extended review cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.1400 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Anesthesiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Covidien, LLC devices

Submission Details

510(k) Number	K213911 FDA.gov
FDA Decision	Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received	December 15, 2021
Decision Date	July 29, 2022
Days to Decision	226 days
Submission Type	Traditional
Review Panel	Anesthesiology (AN)
Summary	Summary PDF
Third-party Review	No - reviewed directly by FDA
Combination Product	No
PCCP Authorized	No

Regulatory Context

Review time vs. panel average

87d slower than avg

Panel avg: 139d · This submission: 226d

Pathway characteristics

Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code	CCK Analyzer, Gas, Carbon-dioxide, Gaseous-phase
Device Class	Class 2 - Special Controls
CFR Regulation	21 CFR 868.1400

What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Anesthesiology devices follow this clearance model.